Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
14. Februar 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
26. Januar 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
12. Januar 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- It is with profound sadness that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a member of its Board of...
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
06. Januar 2022 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference
05. Januar 2022 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
05. Januar 2022 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
21. Dezember 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- New IND Expands Liver Disease Pipeline for CRV431 - - IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment - - New IND Provides for Complementary...
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
30. November 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
16. November 2021 08:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
10. November 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...